The multidrug-resistant yeast pathogen Candida auris continues to cause outbreaks and clusters of clinical cases worldwide. Previously, we developed a real-time PCR assay for the detection of C. auris from surveillance samples (L. Leach, Y. Zhu, and S. Chaturvedi, J Clin Microbiol 56:e01223-17, 2018, https://doi.org/10.1128/ JCM.01223-17). The assay played a crucial role in the ongoing investigations of the C. auris outbreak in New York City. To ease the implementation of the assay in other laboratories, we developed an automated sample-to-result real-time C. auris PCR assay using the BD Max open system. We optimized sample extraction at three different temperatures and four incubation periods. Sensitivity was determined using eight pools of patient samples, and specificity was calculated using four clades of C. auris and closely and distantly related yeasts. Three independent extractions and testing of two patient sample pools in quadruplicate yielded assay precision. BD Max optimum assay conditions were as follows: DNA extraction at 75°C for 20 min and the use of PerfeCTa multiplex quantitative PCR (qPCR) ToughMix. The limit of detection (LOD) of the assay was one C. auris CFU/PCR. We detected all four clades of C. auris without cross-reactivity to other yeasts. Of the 110 patient surveillance samples tested, 50 were positive for C. auris using the BD Max system with 96% clinical sensitivity and 94% accuracy compared to the results of the manual assay. The BD Max assay allows high-throughput C. auris screening of 180 surveillance samples in a 12-h workday. C andida auris, an emerging multidrug-resistant yeast pathogen, continues to cause outbreaks and clusters of clinical cases worldwide (1, 2). There are ongoing efforts to devise better diagnostic approaches for the rapid detection of C. auris in clinical and surveillance samples (3-5). Previously, we developed and validated a manual real-time PCR assay for the direct detection of C. auris from surveillance samples at the New York State Department of Health (NYSDOH) Mycology Laboratory (3). The laboratorydeveloped test (LDT) enabled NYSDOH laboratory scientists and epidemiologists to carry out unprecedented surveillance and testing in hospitals and health care facilities in New York City. To date, over 13,000 clinical samples from 151 health care facilities and over 1,000 C. auris isolates were processed (S. Chaturvedi, unpublished data). The Candida auris LDT, standard operating procedures, and validation results were shared extensively with hospital, commercial, and public health laboratories. However, the C. auris LDT is not amenable to automation and high-throughput screening, and adoption of the LDT has progressed slowly while the affected facilities and sample numbers continue to grow. Therefore, we developed and validated a real-time PCR assay for C. Citation Leach L, Russell A, Zhu Y, Chaturvedi S, Chaturvedi V. 2019. A rapid and automated sample-to-result Candida auris real-time PCR assay for high-throughput testing of surveillance samples with the B...